Attention deficit hyperactivity disorder: The state of the matter and further research approaches;Trastorno por déficit de atención/hiperactividad: Estado de la cuestión y futuras líneas de investigación

Revista de Neurologia

Volumn 46, Issue 6, 2008, Pages 365-372

  Cardo, Esther ^a   Servera, M ^b  

^a HOSPITAL SON LLÀTZER   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Attention deficit hyperactivity disorder; Diagnosis; DSM IV; Research; Review; Therapy

Indexed keywords

ATTENTION DEFICIT DISORDER; CLINICAL RESEARCH; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HUMAN; NEUROBIOLOGY; REVIEW;

EID: 41849093343     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4606.2007529     Document Type: Review

References (78)

1. Martin A. The hard work of growing up with ADHD. Am J Psychiatry 2005; 162: 1575-7.
2. McArdle P. Attention-deficit hyperactivity disorder and life-span development. Br J Psychiatry 2004; 184: 468-9.
3. Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 1495-503.
4. Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry 2006; 67 (Suppl 8): S27-31.
5. Pineda DA, Lopera F, Palacio JD, Ramírez D, Henao GC. Prevalence estimations of atención-deficit/hyperactivity disorder: differential diagnoses and comorbidities in a Colombian simple. Int J Neurosci 2003; 113: 49-71.
6. Cardo E, Servera M, Llobera J. Estimación de la prevalencia del trastorno por déficit de atención e hiperactividad en población normal de la isla de Mallorca. Rev Neurol 2007; 44: 10-4.
7. Moffitt TE, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? Am J Psychiatry 2007; 164: 856-8.
8. Thapar A, Langley K, Asherson P, Gill M. Gene-environment interplay in attention-deficit hyperactivity disorder and the importance of a developmental perspective. Br J Psychiatry 2007; 190: 1-3.
9. Peña JA, Montiel-Nava C. Trastorno por déficit de atención/hiperactividad: ¿mito o realidad? Rev Neurol 2003; 36: 173-9.
10. American Psychiatric Association. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Washington:APA; 2000. p. 85-93.
11. McGough JJ, McCracken JT. Adult attention deficit hyperactivity disorder: moving beyond DSM-IV. Am J Psychiatry 2006; 163: 1673-5.
12. Sergeant J. Are we ready for endophenotypes in attention deficit hyperactivity disorder? Rev Bras Psiquiatr 2005; 27: 262-3.
13. Frick PJ, Lahey BB, Applegate B, Kerdyck L, Ollendick T, Hynd GW, et al. DSM-IV field trials for the disruptive behavior disorders: symptom utility estimates. J Am Acad Child Adolesc Psychiatry 1994; 33: 529-39.
14. Achenbach TM. Advancing assessment of children and adolescents: commentary on evidence-based assessment of child and adolescent disorders. J Clin Child Adolesc Psychol 2005; 4: 541-7.
15. Power TJ, Costigan TE, Leff SS, Eiraldi RB, Landau S. Assessing ADHD across settings: contributions of behavioral assessment to categorical decision making. J Clin Child Psychol 2001; 30: 399-412.
16. Cardo E, Bustillo M, Servera M. Valor predictivo de los criterios del DSM-IV en el diagnóstico del trastorno por déficit de atención/hiperactividad y sus diferencias culturales. Rev Neurol 2007; 44 (Suppl 2): S19-22.
17. Bauermeister JJ, Shrout PE, Chavez L, Rubio-Stipec M, Ramirez R, Padilla L, et al. ADHD and gender: are risks and sequela of ADHD the same for boys and girls? J Child Psychol Psychiatry 2007; 48: 831-9.
18. Servera M, Cardo E. ADHD Rating Scale-IV en una muestra escolar española: datos normativos y consistencia interna para maestros, padres y madres. Rev Neurol 2007; 45: 393-9.
19. Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychological subtypes? Biol Psychiatry 2005; 57: 1224-30.
20. Baeyens D, Roeyers H, Walle JV. Subtypes of attention-deficit/ hyperactivity disorder (ADHD): distinct or related disorders across measurement levels? Child Psychiatry Hum Dev 2006; 36: 403-17.
21. Biederman J, Gao HT, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry 2006; 60: 1106-10.
22. Ortiz-Luna JA, Acle-Tomasini G. Diferencias entre padres y maestros en la identificación de síntomas del trastorno por déficit de atención con hiperactividad en niños mexicanos. Rev Neurol 2006; 42: 17-21.
23. Fernández-Jaén A. Trastorno por déficit de atención e hiperactividad y retraso mental. Rev Neurol 2006; 42 (Suppl 2): S25-7.
24. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006; 67 (Suppl 8): S7-12.
25. Cabral P. Attention deficit disorders: are we barking up the wrong tree? Eur J Paediatr Neurol 2006; 10: 66-77.
26. Cortese S, Konofal E, Yateman N, Mouren MC, Lecendreux M. Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systematic review of the literature. Sleep 2006; 29: 504-11.
27. Snyder SM, Hall JR. A meta-analysis of quantitative EEG power associated with attention-deficit hyperactivity disorder. J Clin Neurophysiol 2006; 23: 440-55.
28. Fassbender C, Schweitzer JB. Is there evidence for neural compensation in attention deficit hyperactivity disorder? A review of the functional neuroimaging literature. Clin Psychol Rev 2006; 26: 445-65.
29. Krain AL, Castellanos FX. Brain development and ADHD. Clin Psychol Rev 2006; 26: 433-44.
30. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 2006; 26: 396-432.
31. Faraone SV, Khan SA. Candidate gene studies of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2006; 67: 13-20.
32. Gilbert DL, Ridel KR, Sallee FR, Zhang J, Lipps TD, Wassermann EM. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology 2006; 31: 442-9.
33. McGough JJ, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatr 2006; 45: 1314-22.
34. Acosta MT. Aspectos genéticos y moleculares en el trastorno por déficit de atención/hiperactividad: búsqueda de los genes implicados en el diagnóstico clínico. Rev Neurol 2007; 44 (Supl 2): S37-41.
35. Mulas F, Mattos L, De la Osa-Langreo A, Gandía R. Trastorno por déficit de atención/hiperactividad: a favor del origen orgánico. Rev Neurol 2007; 44 (Supl 3): S47-9.
36. Ramos-Quiroga JA, Ribasés-Haro M, Bosch-Munsó R, Cormand-Rifà B, Casas M. Avances genéticos en el trastorno por déficit de atención/hiperactividad. Rev Neurol 2007; 44 (Supl 3): S51-2.
37. Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatr 2006; 67 (Suppl 8): S21-6.
38. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 2006; 26: 466-85.
39. Dickstein SG, Bannon K, Castellanos FX, Milham MP. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry 2006; 47: 1051-62.
40. Romero-Ayuso DM, Maestú F, González-Marques J, Romo-Barrientos C, Andrade JM. Disfunción ejecutiva en el trastorno por déficit de atención con hiperactividad en la infancia. Rev Neurol 2006; 42: 265-71.
41. Servera M, Cardo E. Children Sustained Attention Task (CSAT): normative, reliability, and validity data. Int J Clin Health Psychol 2006; 6: 697-707.
42. Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 2006; 15: 13-50.
43. Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic releases oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006; 16: 441-55.
44. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006; 16: 351-6.
45. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160: 82-90.
46. Greenhill LL, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1284-93.
47. Grizenko N, Bhat M, Schwartz G, Ter-Stepanian M, Joober R. Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. J Psychiatr Neurosci 2006; 31: 46-51.
48. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon EA. Randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006; 9: 476-85.
49. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006; 13: 50-62.
50. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006; 149: 112-9.
51. Wilens TE, Kratochvil C, Newcorn JH, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006; 45: 149-57.
52. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006; 149: 112-9.
53. Biederman J, Gao HT, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry 2006; 60: 1106-10.
54. Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther 2006; 28: 280-93.
55. Gilbert DL, Ridel KR, Sallee FR, Zhang J, Lipps TD, Wassermann EM. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology 2006; 31: 442-9.
56. Gibson AP, Bettinger TL, Patel NC, Crismon M. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006; 40: 1134-42.
57. Ashton H, Gallagher P, Moore B. The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder. J Psychopharmacol 2006; 20: 602-10.
58. Hechtman L. Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep 2006; 8: 398-408.
59. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamphetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Asses 2006; 10 (Suppl 23): 1-162.
60. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 503-11.
61. Swanson JM, Greenhill LL, López FA, Sedillo A, Earl CQ, Jiang JG, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatr 2006; 67: 137-47.
62. Rubinstein S, Malone MA, Roberts W, Logan WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006; 16: 404-15.
63. Poulton A. Growth and sexual maturation in children and adolescents with attention deficit hyperactivity disorder. Curr Opin Pediatr 2006; 18: 427-34.
64. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006; 45: 415-21.
65. Wells KC, Chi TC, Hinshaw SP, Epstein JN, Pfiffner L, Nebel-Schwalm M, et al. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attentiondeficit/hyperactivity disorder. J Consult Clin Psychol 2006; 74: 649-57.
66. Holtmann M, Stadler C. Electroencephalographic biofeedback for the treatment of attention-deficit hyperactivity disorder in childhood and adolescence. Expert Rev Neurother 2006; 6: 533-40.
67. Beauregard M, Levesque J. Functional magnetic resonance imaging investigation of the effects of neurofeedback training on the neural bases of selective attention and response inhibition in children with attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback 2006; 31: 3-20.
68. Levesque J, Beauregard M, Mensour B. Effect of neurofeedback training on the neural substrates of selective attention in children with attention-deficit/hyperactivity disorder: a functional magnetic resonance imaging study. Neurosci Lett 2006; 394: 216-21.
69. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18: 155-72.
70. Trebaticka J, Kopasova S, Hradecna Z, Cinovsky K, Skodacek I, Suba J, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry 2006; 15: 329-35.
71. Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF, et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr 2005; 164: 758-67.
72. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006; 67 (Suppl 8): 38-45.
73. Servera M. Modelo de autorregulación de Barkley aplicado al trastorno por déficit de atención con hiperactividad: una revisión. Rev Neurol 2005; 40: 358-68.
74. Pelham WE, Burrows-Maclean L, Gnagy EM, Fabiano GA, Coles EK, Tresco KE, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005; 13: 111-26.
75. Luman M, Oosterlaan J, Sergeant JA. The impact of reinforcement contingencies on AD/HD: a review and theoretical appraisal. Clin Psychol Rev 2005; 25: 183-213.
76. Monastra VJ, Lynn S, Linden M, Lubar JF, Gruzelier J, LaVaque TJ. Electroencephalographic biofeedback in the treatment of attentiondeficit/ hyperactivity disorder. Appl Psychophysiol Biofeedback 2005; 30: 95-114.
77. Ramos-Quiroga JA, Bosch-Munso R, Castells-Cervelló X, Nogueira-Morais M, García-Giménez E, Casas-Brugué M. Trastorno por déficit de atención con hiperactividad en adultos: caracterización clínica y terapéutica. Rev Neurol 2006; 42: 600-6.
78. Safren SA. Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry 2006; 67 (Suppl 8): S46-50.